Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Color Diagnostics, |
RCV001181968 | SCV001347237 | likely benign | Hereditary cancer-predisposing syndrome | 2019-10-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002068303 | SCV002393937 | likely benign | Hereditary nonpolyposis colorectal neoplasms | 2024-09-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV001181968 | SCV002670854 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-08-05 | criteria provided, single submitter | clinical testing | The c.783C>T variant (also known as p.F261F), located in coding exon 9 of the MLH1 gene, results from a C to T substitution at nucleotide position 783. This nucleotide substitution does not change the at codon 261. This variant has been identified in a proband whose Lynch syndrome-associated tumor was microsatellite stable and demonstrated normal mismatch repair protein expression by immunohistochemistry (Li S et al. J. Med. Genet. 2020 Jan;57:62-69; Ambry internal data). This nucleotide position is well conserved in available vertebrate species. In silico splice site analysis for this alteration is inconclusive. RNA studies have demonstrated that this alteration results in an incomplete splice defect; the clinical impact of this abnormal splicing is unknown at this time (Ambry internal data). Based on the available evidence, the clinical significance of this variant remains unclear. |
Myriad Genetics, |
RCV005245745 | SCV005900018 | benign | Colorectal cancer, hereditary nonpolyposis, type 2 | 2024-11-20 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. |